Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 1.00 |
| ▸ | BCHE | P06276 | 7/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | PKM | P14618 | 1/20 | 0.79 |
| ▸ | UBE2N | P61088 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.79 |
| ▸ | APP | P05067 | 9/20 | 0.76 |
| ▸ | CASP6 | P55212 | 1/20 | 0.66 |
| ▸ | PDE5A | O76074 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12175837 | 0.90 | RAD52 (1.00) | ACHEBCHERAD52KDM4EALDH1A1 | |
| SCHEMBL16280679 | 0.89 | ACHE (0.80) | ACHEBCHERAD52KDM4EALDH1A1 | |
| SCHEMBL3117720 | 0.88 | BCHE (0.78) | ACHEBCHERAD52KDM4EALDH1A1 | |
| SCHEMBL2256496 | 0.88 | ACHE (0.78) | ACHEBCHERAD52KDM4EALDH1A1 | |
| SCHEMBL21055805 | 0.86 | ACHE (0.75) | ACHEBCHERAD52KDM4EALDH1A1 | |
| SCHEMBL3639768 | 0.85 | RAD52 (0.82) | ACHEBCHERAD52KDM4EALDH1A1 | |
| SCHEMBL21055807 | 0.84 | BCHE (0.72) | ACHEBCHERAD52KDM4EALDH1A1 | |
| SCHEMBL25867300 | 0.84 | BCHE (0.71) | ACHEBCHERAD52KDM4EALDH1A1 | |
| SCHEMBL3636779 | 0.84 | ACHE (1.00) | ACHEBCHERAD52KDM4EALDH1A1 | |
| SCHEMBL3640101 | 0.83 | RAD52 (0.79) | ACHEBCHERAD52KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323007-B1 | N2N N4-disubstituted quinazoline-2,4-diamines and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323007-B1 | N2N N4-disubstituted quinazoline-2,4-diamines and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-06-18 | — | — | US | disclosed |
| US-20150080409-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | UNIVERSITY OF SOUTH FLORIDA (A FLORIDA NON-PROFIT CORPORATION) (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080409-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | UNIVERSITY OF SOUTH FLORIDA (A FLORIDA NON-PROFIT CORPORATION) (US) | 2015-03-19 | — | — | US | disclosed |
| US-8906918-B1 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (A FLORIDA NON-PROFIT CORPORATION) (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906918-B1 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (A FLORIDA NON-PROFIT CORPORATION) (US) | 2014-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323007-B1 | N2N N4-disubstituted quinazoline-2,4-diamines and uses thereof | NQO2, NQO1, NIT2 | ACHE 14/4885BCHE 224/4885RAD52 1732/4885 |
| US-20150080409-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | SYNCRIP, HNMT, IL5 | ACHE 8/4885BCHE 102/4885RAD52 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.